Allogeneic hematopoietic stem cells transplantation is one of the effective methods treating patients with diseases blood system. Establishment complete (100%) donor chimerism among main indicators successful in such cases. Monitoring makes it possible both to assess graft acceptance, and also potentially predict risk developing primary/secondary failure, relapse, graft-versus-host disease. The...

Background: Burkitt lymphoma is a common subtype of non-Hodgkin lymphoma in children. It has a rapid and aggressive clinical course with frequent involvement of bone marrow and central nervous system. Systemic chemotherapy is the mainstay of the treatment for this malignancy in children. In this systematic review, we discuss autologous and allogeneic hematopoietic stem cell transplantation (HSC...

Allogeneic hematopoietic stem cell transplant is safe and curative treatment modality for many hematologic diseases. Expanding alternative donor options such as haploidentical hematopoietic stem cell transplantation and umbilical cord blood, taken together with enhanced outcomes of matched unrelated donors, has resulted in a advisable donor for most patients with an hematopoietic stem cell tran...

in this center, from 1991 to 2002, 89 chronic myelogenous leukemic (cml) patients, age ranging between 8-48 years with a median age of 29, underwent hematopoietic stem cell transplantation. eighty-eight patients were in the first chronic phase of disease. twenty-three patients received bone marrow transplantation (bmt) and 66 patients received peripheral blood stem cell transplantations (pbsct)...

introduction: allogeneic hematopoietic cell transplantation (hsct) is the only therapeutic modality capable of correcting the hematologic manifestations of fanconi anemia (fa). the development  of well  tolerated,  immunosuppressive  conditioning  regimens  for fa patients  undergoing hsct has proven to be a rather challenging task for hematologists. methods: we analyzed the outcome of 30 fa pa...

conclusions in iran, hsct has been successfully adapted in routine clinical care. recently, new methods such as double cord blood and haploidentical transplantation have been used to treat many life-threatening diseases. results about 78.2% of the patients (2530 of 3237) remained alive between one to 211 months after stem cell transplantation. nearly, 21.8% (707) of our patients died after stem...

High-dose chemotherapy followed by autologous hematopoietic stem cell transplantation has been explored as a method to enhance the efficacy of chemotherapy for advanced solid tumors. The failure of autologous hematopoietic stem cell transplantation to prolong survival in patients with metastatic solid tumors has sparked interest recently in studies exploring the potential of allogeneic hematopo...

In contrast to allogeneic hematopoietic stem cell transplantation, the current dogma is not an evidence of graft-versus-tumor effect in autologous hematopoietic stem cell transplantation; thus, it is assumed that autologous hematopoietic stem cell transplantation only relies on the high-dose chemotherapy to improve clinical outcomes. However, recent studies argue in favor of the existence of an...

Allogeneic and autologous hematopoietic stem cell transplantations are important therapeutic options for patients with hematologic disorders. Hemostatic complications are frequent after hematopoietic stem cell transplantation with a considerable morbidity and mortality. The incidence of bleedings and thrombosis is highest in the first few weeks after transplantation, but may also occur later. H...